The potential of evinacumab, a monoclonal antibody targeting angiopoietin-like 3, for reducing triglyceride levels was tested in patients with severe hypertriglyceridemia due to differing genetic etiologies.
- Robert S. Rosenson
- Daniel Gaudet
- Daniel J. Rader